In support, circadian signals hold promise as anti-CTLA-4 therapeutic complements given their role in an alternative immune pathway that induces TH17 differentiation and activation, thus boosting host anti-tumor immunity [77]. This evidence concerns the gene CTLA4 and neoplasm.